Breaking News

Financial Results: Patheon 4Q12

December 17, 2012

CMO revenues up 18% in the quarter

Patheon

4Q Revenues: $210.0 million (flat) 

4Q Loss: $23.1 million (loss of $9.9 million in 4Q11)

YTD Revenues: $749.1 million (+7%)

YTD Loss: $106.7 million (loss of $16.4 million YTD11)

Comments: Commercial manufacturing revenues in the quarter were $172.7 million, up 18%, and for the year were $610.7 million, up 7%. Pharmaceutical Development Services revenues in the quarter were $37.5 million, up 7%, and for the year were $138.4 million, up 9%. The loss before discontinued operations was $106.4 million YTD compared to a loss of $15.8 million last year, primarily due to the asset impairment charge of $57.9 million related to closing the Swindon, UK facility.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016